Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat with Atezolizumab and Chemotherapy in ES-SCLC
NCT04631029Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Dose Limiting Toxicities up to 21 days, Number of Participants Experiencing Grade 3 and 4 Adverse Events up to 30 days and 1 more. Started Apr 2021; status: completed.
02
Drugs
entinostat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04631029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631029.